Mereo BioPharma posted a net loss of $7.0 million for Q3 2025, significantly reduced from the prior year. Increased R&D spending reflects continued development of setrusumab and alvelestat. Cash reserves stand strong at $48.7 million, with operations funded into 2027.

Mereo Biopharma posted a Q2 2025 net loss of $14.6 million, primarily due to foreign currency loss and increased R&D expenses linked to its osteogenesis imperfecta program. G&A expenses declined from the prior year due to ADR reimbursements and lower professional fees. With $56.1 million in cash, the company expects to fund operations into 2027 as it progresses late-stage trials.

Mereo BioPharma reported a net loss of $12.9 million for the first quarter of 2025, compared to a net loss of $9.0 million in the same period last year. The company's cash and cash equivalents stood at $62.5 million as of March 31, 2025, which is expected to fund operations into 2027. Progress continues in the Phase 3 Orbit study of setrusumab, with a read-out anticipated in mid-2025 or Q4 2025.

Mereo BioPharma reported a net loss of $43.3 million for the full year ended December 31, 2024, compared to a net loss of $29.5 million in 2023. The company's cash and cash equivalents stood at $69.8 million as of December 31, 2024, with operations expected to be funded into 2027.

Mereo BioPharma reported a net loss of $12.3 million for the second quarter of 2024. Cash and cash equivalents totaled $87.4 million as of June 30, 2024, expected to fund operations into 2027. Phase 3 studies of setrusumab in OI were fully enrolled and positive Phase 2 data was announced.

Mereo BioPharma reported a net loss of $29.5 million for the full year ended December 31, 2023, with cash and cash equivalents of $57.4 million as of the same date. The company expects its cash to fund operations into 2026. Partnering discussions for alvelestat are progressing, with plans to initiate Phase 3 with a partner around the end of 2024.